EDMONTON, ALBERTA--(Marketwire - Aug. 24, 2011) - Quicker recovery from infections, lower ultimate cost, and less opportunity for bacteria to develop resistance. That is the message that Dr. Merle Olson, Research Director at Innovotech (TSX VENTURE:IOT) will be taking to the international Central Veterinary Conference in Kansas City, Missouri, about the new Innovotech line of veterinary tests that are now available on a worldwide basis through Spectrum Labs' becSCREEN(TM) assay.
Innovotech's tests focus on providing antibiotic treatment options for chronic infections caused by bacteria in a biofilm state. It is a new technology. Traditional testing has been designed to test bacteria in a free-floating state, which is not how bacteria are found in chronic infections. Biofilms can be up to 1000 times more resistant to treatment than the same organism in a free-floating state.
Spectrum Labs has a respected international reputation in the field of veterinary diagnostics and Innovotech's tests provide them with another opportunity to deliver the best technology available, this time to find treatments for chronic bacterial infections.
For information on having your pet or other animal tested, contact Spectrum Labs at http://www.becscreen.com
About the CVC Conference
For more than 20 years, CVC's vision has been to provide veterinarians, veterinary technicians, practice managers, and team members the best convention experience possible by offering premium educational programming, expert clinical education, hands-on labs and workshops, practice management programs, and team training sessions. The CVC conference in Kansas City, August 24-30, 2011, is expected to attract approximately 6,500 attendees. For more information visit http://www.thecvc.com/
About Innovotech Inc.
Innovotech Inc. is a pioneer in the field of biofilm product development, focused on providing innovative and practical solutions to medical, agricultural and industrial problems caused by microbial biofilms. Biofilms are organized communities of microorganisms that exist in virtually every natural environment and are responsible for a host of diseases in human health, animal health and agriculture. There are few products or regulatory standards, aside from those of Innovotech, designed specifically for biofilm-forming organisms.
Innovotech has a broad range of products that address the issue of biofilms within a number of different industries, including commercially available products in three market segments; the MBEC Assay(TM), bioFILM PA(TM) and InnovoSCEPT veterinary kits. The MBEC Assay(TM) is a high throughput biofilm growth device that was recently approved as an ASTM International standard. bioFILM PA(TM) is the first diagnostic kit to assist physicians in the selection of the most effective combination antibiotic treatment of patients with biofilm-based chronic lung infections, while the InnovoSCEPT veterinary kits are designed to determine the most effective antibiotic treatment for infections in both large and small animals.
Innovotech also has two products in advanced stages of development; Agress(R) is a unique, environmentally friendly seed treatment and plant spray designed to protect crops against both bacterial and fungal infections and Sani-Lux(TM) is a light-activated, natural hard surface sanitizer.
About Spectrum Labs Inc.
Spectrum specializes in allergy testing and treatment, dedicated to veterinarians and their patients in 46 countries. Spectrum Labs has spent the last twenty plus years researching, developing, compiling, questioning and testing the traditional and emerging alike to uncover the best and most reliable tools and methodologies. Please visit www.vetallergy.com for more information on the company as well as its services and to get a preview of what is to come with both the becASSAY for biofilms and the all new SPOT Platinum test. The core focus of the company has always been and will remain quality results and superlative customer service.
Connect with us:
This document may contain forward-looking statements that are predictive in nature and subject to risks and uncertainties that cannot be predicted or quantified; consequently, actual results may differ materially from past results and those expressed or implied by any forward-looking statements. The Company undertakes no obligation to publicly make or update any forward-looking statements, except as required by applicable law.The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.